Abstract
Bone scintigraphy with Tc-99m-diphosphonate analogs are widely used in staging, restaging, and monitoring the therapy effectiveness of various cancer types. Bone-seeking agents are excreted through urination, resulting in the visualization of either anatomical abnormalities or pathological conditions of the kidneys and bladder. We present a case of a 63-year-old man with urinary bladder carcinoma depicted on whole body planar and single-photon emission computed tomography/computed tomography images.
Keywords: Bone scintigraphy, SPECT/CT, urinary bladder carcinoma, nuclear medicine
References
De Geeter F, Goethals L. Utility of pelvic bone SPET in imaging urinary bladder filling defects in urinary bladder carcinoma. Hell J Nucl Med 2010;13:59-62.
Niederkohr RD, Chiu E, Katzel JA. 99mTc-oxidronate uptake within urothelial carcinoma confirmed with SPECT/CT imaging. Clin Nucl Med 2013;38:655-657.
Lin Y, Lu YY, Wang HY, Tsai SC, Lin WY. Accidental finding of bladder cancer in 99mTc methylene diphosphonate whole-body bone scan. Clin Nucl Med 2013;38:643-645.
Wright CL, Sharma A. Unusual appearance for urinary bladder obstruction detected with 99mTc-MDP bone scintigraphy. Clin Nucl Med 2015;40:967-968.
Bilchik TR, Spencer RP. Bladder variants on bone and renal imaging. Clin Nucl Med 1993;18:60-67.
Duong RB, Gelfand MJ, Volarich DT, Williams P. Urinary tract imaging -- filling defect in the urinary bladder. Semin Nucl Med 1983;13:383-385.
Mandell GA, Harcke HT. Extrinsic causes of vesical filling defects on scintigraphy. Clin Nucl Med 1987;12:204-207.
Stewart CA, Siegel ME, NafisWA, Wood LA. Bone scan of recurrent colon carcinoma involving the sacrum and urinary bladder. Clin Nucl Med 1989;16:513-514.
